| 证券代码：603707 | 证券简称：健友股份 | 公告编号：2023-071 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 许可协议暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、本次交易概述 2023 年 6 月 27 日,南京健友生化制药股份有限公司（以下简称"公司""健 友股份"）召开第五届董事会第二次会议，审议通过了《关于公司子公司与 Xentria 签署许可协议暨关联交易的议案》，关联董事唐咏群、谢菊华回避表决， 独立董事发表了事前认可意见和同意的独立意见。 2023 年 7 月 18 日，南京健友生化制药股份有限公司（以下简称"公司""健 友股份"） 召开 2023 年第二次临时股东大会，审议通过了《关于公司子公司与 Xentria 签署许可协议暨关联交易的议案》，关联股东谢菊华、唐咏群回避表决。 公司的全资子公司香港健友实业有限公司（以下简称"香港健友""被许可 方代表"）及香港健友控股子 ...

| 证券代码：603707 | 证券简称：健友股份 | 公告编号：2023-070 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于"健友转债"转股结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 自 2021 年 7 月 15 日起，健友转债转股价格变为 32.20 元/股。因公司实施 2021 年限制性股票激励计划预留授予，自 2022 年 6 月 10 日起，健友转债转股价格变 为 32.19 元/股。因公司实施 2021 年年度权益分派，自 2022 年 7 月 11 日起，健 友转债转股价格变为 24.65 元/股。因公司实施 2022 年年度权益分派，于 2023 年 7 月 7 日起，健友转债转股价格变为 24.54 元/股。 重要内容提示： 转股情况： 截至 2023 年 9 月 30 日，累计已有人民币 690,000 元"健友转债"转为公司 普通股，累计转股股数 16,853 股，占转股前公司 ...

| 股票代码：603707 | 股票简称：健友股份 公告编号：2023-069 | | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | 南京健友生化制药股份有限公司 关于不向下修正"健友转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 1、公司于2020年7月10日起因实施2020年限制性股票激励计划，"健友转债" 的转股价格由54.97元/股调整为54.96元/股。具体内容详见公司2020年7月10日披露 的《南京健友生化制药股份有限公司关于"健友转债"转股价格调整的公告》（公 告编号：2020-061）。 2、公司于2020年7月23日起因实施2019年年度利润分配方案，"健友转债"的 转股价格由54.96元/股调整为42.05元/股。具体内容详见公司2020年7月17日披露的 《南京健友生化制药股份有限公司关于"健友转债"转股价格调整的提示性公告》 （公告编号：2020-070）。 3、公司于2021年6月25日起因实施2021年限制性股票激励计划，"健友转债" ...

| 证券代码：603707 | 证券简称：健友股份 | 公告编号：2023-068 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于"健友转债"预计满足 转股价格修正条款的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、可转债的发行上市概况 经中国证券监督管理委员会《关于核准南京健友生化制药股份有限公司公开 发行可转换公司债券的批复》（证监许可[2020]603 号）核准，南京健友生化制 药股份有限公司（以下简称"公司"）公开发行了 5,031,900 张可转换公司债券 （以下简称"可转债"或"健友转债"），每张面值人民币 100 元，发行总额人 民币 5.0319 亿元，本次可转债存续期限为发行之日起六年，即自 2020 年 4 月 23 日至 2026 年 4 月 22 日。 1、可转债转股价格修正条款 （1）修正权限与修正幅度 在本次可转债存续期间，当公司股票在任意连续三十个交易日中至少有十五 个交易日的收盘价 ...

Financial Performance - Revenue for the first half of 2023 reached RMB 2,303,732,565.40, a year-on-year increase of 16.63%[17] - Net profit attributable to shareholders of the listed company was RMB 624,500,188.97, up 1.70% compared to the same period last year[17] - Net cash flow from operating activities increased by 26.42% to RMB 630,364,246.90[17] - Basic earnings per share increased by 2.63% to 0.39 yuan per share compared to the same period last year[18] - Weighted average return on equity decreased by 1.23 percentage points to 9.63%[18] - Non-recurring gains and losses amounted to 13,173,527.77 yuan, including government subsidies of 15,247,914.63 yuan[21][22] - The company achieved a revenue of 2.30 billion yuan in the first half of 2023, a year-on-year increase of 16.63%, with overseas sales accounting for 73.11% of total revenue at 1.68 billion yuan, and domestic sales at 619 million yuan, accounting for 26.89%[39] - Net profit attributable to the parent company in the first half of 2023 was 624.50 million yuan, a year-on-year increase of 1.70%, driven by growth in the company's formulation sales[39] - The company's U.S. subsidiary, Meitheal, achieved sales revenue exceeding 800 million yuan in the first half of 2023, a year-on-year increase of 49.70%[40] - The company's CDMO business revenue grew by over 40% in the first half of 2023, driven by strategic collaborations with global clients[40] - The company achieved a revenue of 2.30 billion yuan in the first half of 2023, a year-on-year increase of 16.63%, with a net profit of 624.50 million yuan, up 1.70% year-on-year[62] - R&D investment in the reporting period was 163.52 million yuan, a year-on-year increase of 24.17%, with a strong R&D team of over 500 people[63] - Revenue increased by 16.63% year-on-year to RMB 2.30 billion in the first half of 2023[69] - R&D expenses grew by 42.46% year-on-year to RMB 150.81 million, reflecting increased investment in innovation[69] - Net profit attributable to the parent company's shareholders was 624,500,188.97 RMB in the first half of 2023, a 1.7% increase from 614,035,642.75 RMB in the same period of 2022[181] - Basic earnings per share (EPS) for the first half of 2023 was 0.39 RMB, compared to 0.38 RMB in the same period of 2022[182] - Total comprehensive income for the first half of 2023 was 629,782,766.18 RMB, a 3.0% increase from 611,113,416.38 RMB in the same period of 2022[182] - Sales expenses rose by 21.4% to 261,555,451.30 RMB in the first half of 2023, compared to 215,454,959.30 RMB in the same period of 2022[178] - Financial expenses showed a net income of 85,700,841.49 RMB in the first half of 2023, compared to 69,193,979.94 RMB in the same period of 2022[178] - The company's total profit for the first half of 2023 was 738,348,951.76 RMB, a 3.2% increase from 715,422,314.44 RMB in the same period of 2022[180] - Income tax expenses increased by 11.7% to 113,834,452.06 RMB in the first half of 2023, compared to 101,951,732.21 RMB in the same period of 2022[180] - Comprehensive income for the first half of 2023 was RMB 510,085,407.48, compared to RMB 606,570,546.08 in the same period last year[185] - Cash flow from operating activities in the first half of 2023 was RMB 630,364,246.90, an increase from RMB 498,607,712.27 in the same period last year[187] - Cash received from sales of goods and services in the first half of 2023 was RMB 2,233,827,146.83, slightly up from RMB 2,178,973,884.58 in the same period last year[186] - Cash paid for goods and services in the first half of 2023 was RMB 1,189,538,431.81, compared to RMB 1,165,380,748.61 in the same period last year[186] - Cash flow from investing activities in the first half of 2023 was negative RMB 37,997,140.78, an improvement from negative RMB 511,030,540.94 in the same period last year[187] - Cash flow from financing activities in the first half of 2023 was negative RMB 298,667,663.85, compared to positive RMB 460,818,279.85 in the same period last year[188] - Net increase in cash and cash equivalents in the first half of 2023 was RMB 307,213,181.99, down from RMB 460,170,306.18 in the same period last year[188] - Cash received from tax refunds in the first half of 2023 was RMB 133,893,037.17, slightly down from RMB 144,194,652.57 in the same period last year[186] - Cash paid to employees in the first half of 2023 was RMB 194,191,605.46, up from RMB 148,338,042.47 in the same period last year[186] - Cash paid for taxes in the first half of 2023 was RMB 178,577,981.96, down from RMB 225,256,986.06 in the same period last year[186] - Net cash flow from investment activities was -36.65 million yuan, compared to 27.25 million yuan in the same period last year[190] - Net cash flow from financing activities was -125.01 million yuan, compared to -67.19 million yuan in the same period last year[190] - The net increase in cash and cash equivalents was 99.64 million yuan, compared to 259.20 million yuan in the same period last year[190] - The total comprehensive income for the period was 629.78 million yuan[192] - The company allocated 185.91 million yuan for profit distribution to shareholders[192] - The total owner's equity at the end of the period was 6.61 billion yuan, an increase from 6.17 billion yuan at the beginning of the period[194] - The company's capital reserve decreased by 3.11 million yuan during the period[192] - The company's undistributed profit increased by 438.59 million yuan during the period[192] - The company's special reserve increased by 71,567.71 yuan during the period[194] - The company's total liabilities and owner's equity at the end of the period was 6.61 billion yuan[194] - The company's total comprehensive income for the first half of 2023 was RMB 607,000,464.30[196] - The company allocated RMB 186,585,548.70 for profit distribution to shareholders[197] - The company's total owner's equity at the end of the period was RMB 5,858,103,612.41[198] - The company's capital reserve increased by RMB 11,928,122.64 during the period[196] - The company's undistributed profit decreased by RMB 7,035,178.45[196] - The company's special reserve increased by RMB 4,116,209.04[198] - The company's total owner's equity at the beginning of the period was RMB 5,402,757,039.30[196] - The company's capital stock increased by RMB 303,438.00[196] - The company's other comprehensive income decreased by RMB 196.10[196] - The company's total owner's equity increased by RMB 455,346,573.11 during the period[196] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 11,095,253,855.79, a 10.84% increase from the end of the previous year[17] - Equity attributable to shareholders of the listed company grew by 7.22% to RMB 6,616,095,822.22[17] - Cash and cash equivalents increased by 26.13% to 1,751,303,798.14 yuan, accounting for 15.78% of total assets[72] - Trading financial assets surged by 36,076.92% to 470,300,000.00 yuan due to increased financial product purchases[72] - Accounts receivable increased by 386.68% to 107,117,814.94 yuan, driven by higher receivables from bills[72] - Prepayments rose by 260.53% to 90,370,653.36 yuan due to increased advance payments for goods[72] - Other receivables grew by 21.42% to 293,760,741.65 yuan, mainly due to increased cooperation funds from Europe and the US[72] - Fixed assets increased by 29.03% to 1,200,956,552.04 yuan, primarily due to the transfer of construction in progress to fixed assets[72][73] - Construction in progress decreased by 92.77% to 18,119,509.44 yuan, as projects were transferred to fixed assets[73] - The company's monetary funds increased to 1,751,303,798.14 yuan as of June 30, 2023, compared to 1,388,512,343.62 yuan at the end of 2022[167] - The company's total assets reached 11,095,253,855.79 yuan as of June 30, 2023, up from 10,010,102,945.14 yuan at the end of 2022[169] - The company's short-term borrowings increased to 2,251,789,666.36 yuan as of June 30, 2023, compared to 1,956,863,361.92 yuan at the end of 2022[169] - The company's accounts receivable increased to 1,009,863,891.94 yuan as of June 30, 2023, up from 952,098,814.39 yuan at the end of 2022[167] - The company's inventory decreased slightly to 5,555,576,976.64 yuan as of June 30, 2023, compared to 5,615,601,457.76 yuan at the end of 2022[168] - The company's fixed assets increased to 1,200,956,552.04 yuan as of June 30, 2023, up from 930,727,070.81 yuan at the end of 2022[168] - The company's total current liabilities increased to 3,340,928,333.11 yuan as of June 30, 2023, compared to 2,704,653,975.08 yuan at the end of 2022[169] - The company's development expenditure increased to 107,377,228.39 yuan as of June 30, 2023, up from 93,236,418.69 yuan at the end of 2022[168] - The company's total non-current assets reached 1,773,423,903.42 yuan as of June 30, 2023, compared to 1,716,038,381.10 yuan at the end of 2022[169] - Total liabilities increased to 4,482,609,220.14 RMB, up from 3,842,932,928.85 RMB in the previous period[170] - Total owner's equity (or shareholder's equity) reached 6,612,644,635.65 RMB, compared to 6,167,170,016.29 RMB previously[171] - Monetary funds increased to 184,669,804.14 RMB from 104,262,654.92 RMB[172] - Accounts receivable rose to 1,455,326,689.74 RMB from 1,200,080,987.96 RMB[172] - Inventory decreased slightly to 4,868,512,114.20 RMB from 4,987,456,425.34 RMB[172] - Total assets amounted to 8,557,447,770.81 RMB, up from 8,427,634,697.16 RMB[173] - Short-term borrowings decreased significantly to 280,957,623.00 RMB from 723,286,608.02 RMB[173] - Long-term borrowings remained stable at 500,000,000.00 RMB[174] - Total owner's equity (or shareholder's equity) increased to 6,152,857,564.88 RMB from 5,827,080,304.22 RMB[175] Product Portfolio and Market Expansion - The company has 86 overseas drug registration certificates and 26 Chinese drug registration certificates[26] - The company's product pipeline includes low molecular weight heparin preparations, anti-tumor preparations, and other high-value-added sterile injections[26] - The company's heparin sodium injection is approved in the US for anticoagulation and antithrombosis[27] - Enoxaparin sodium injection is approved in multiple countries including the US, UK, Germany, and Canada for the prevention of venous thromboembolism[27] - The company's dalteparin sodium injection is approved in China for the treatment of acute deep vein thrombosis and prevention of thrombosis related to surgery[27] - The company's nadroparin calcium injection is approved in China for the prevention of thrombosis and treatment of deep vein thrombosis[27] - The company's atracurium besylate injection is approved in the US for skeletal muscle relaxation during general anesthesia[27] - The company's product portfolio includes 50 injectable drugs, with 38 approved in the US market and 12 in the Chinese market[29][30][31][32] - Key products include Bendamustine Hydrochloride for Injection (used in the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma) and Mitomycin for Injection (used in the treatment of gastric cancer, lung cancer, breast cancer, etc.)[29][31] - The company is expanding its presence in the European and global markets, particularly with the registration of enoxaparin formulations in more countries[32] - The company maintains long-term stable supply relationships with major global heparin preparation manufacturers, including Pfizer, Gland, and Sanofi[32] - Heparin API business serves as a cash flow provider and foundation for the company's sterile injectable domestic and international expansion[32] - The company obtained multiple drug registration approvals, including Niraparib Injection, Rocuronium Bromide Injection, Bendamustine Hydrochloride for Injection, and Plerixafor Injection, further enriching its product pipeline[39] - The company's CDMO business focuses on providing differentiated biopharmaceutical CDMO services in regulated markets, leveraging global regulatory experience to capture higher-value service revenues[33] - The company established a Biopharmaceutical Division with platforms for protein design, drug delivery systems, molecular biology, and cell biology to enhance innovation capabilities[34] - The company's sterile injection production lines are certified by the U.S. FDA and comply with GMP and cGMP standards, ensuring product quality and safety[36] - The company's domestic formulation sales benefited from the centralized procurement policy, with products like Enoxaparin Sodium Injection and Nadroparin Calcium Injection winning bids in the 8th national drug procurement round[40] - The company's global CDMO business targets sterile injection R&D and production, serving global pharmaceutical companies and domestic innovators with a focus on expanding market demand and reducing costs[38] - The company's products are primarily focused on the anticoagulant and oncology markets, which have significant growth potential[45] - The company provides CDMO services to global and domestic pharmaceutical companies, leveraging advanced process R&D capabilities and production facilities[48] - The company has over 500 R&D personnel, including more than 80 with master's or doctoral degrees, and collaborates with R&D teams in the US and Israel[54] - The company operates four R&D centers in Nanjing, Chengdu, the US, and Israel, focusing on nucleic acid-based therapies, monoclonal antibody development, biopharmaceutical innovation, and clinical research respectively[54] - The company has established a peptide drug R&D platform using solid-phase synthesis technology, covering anticoagulation, reproductive, endocrine, and rare disease biologics[55] - The company has developed advanced complex formulation platforms, including sustained-release injections, liposomes, and auto-injector technologies[55] - The company has a strong track record of obtaining ANDA approvals, ranking first among domestic peers in the number of ANDA approvals[56] - The company has successfully launched generic drugs before the expiration of original patents, accelerating market penetration and product pipeline development[56] - The company's R&D strategy focuses on expanding from heparin-based products to oncology, immunomodulation, metabolic, digestive, and central nervous system diseases, while exploring nucleic acid-based drugs[54] - The company has 6 FDA-approved production lines with high automation and stable processes, significantly improving production efficiency and quality[57] - The company completed the acquisition of Meitheal, enhancing its overseas marketing channels and understanding of the US market[59] - Meitheal has established long-term stable relationships with GPOs, IDN/PNs, and the top three US wholesalers, supporting rapid growth in US sales[60] - The company has a complete sales channel and operational experience in the US market, with localized marketing strategies and deep integration with Meitheal[60] - The company is expanding its CDMO capabilities, attracting global and domestic pharmaceutical companies with its marketing and product development capabilities[61] - The company is optimizing its product structure and expanding production capacity through FDA-approved projects, enhancing its market position and competitiveness[58] - The company has 12 R&D projects in progress, with 7 projects in the stability testing phase and 5 projects under regulatory approval[64] - 7 drugs were approved by the US FDA during the reporting period, including Plerixafor Injection and Bupivacaine Hydrochloride Injection[64] - The company's US subsidiary achieved sales revenue exceeding RMB 800 million in the first half of 2023, a year-on-year increase of 49.70%[

南京健友生化制药股份有限公司 关于 2023 半年度募集资金存放与实际使用情况专项报告 南京健友生化制药股份有限公司 2023 年半年度募集资金存放与实际使用情况专项报告 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》、《上海 证券交易所股票上市规则》、《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 等有关规定，现将南京健友生化制药股份有限公司（以下简称"公司"或"本公司"）2023 半 年度募集资金存放与实际使用情况说明如下。 一、募集资金基本情况 （一）实际募集资金金额、资金到账情况 2020年12月第二次发行可转换公司债券募集资金 经中国证券监督管理委员会《关于核准南京健友生化制药股份有限公司公开发行可转换 公司债券的批复》（证监许可[2020]2658号）的批准，公司获准发行面值总额78,000万元可转 换公司债券，期限6年，发行价格为每张面值100元人民币，按面值发行，募集资金总额人民币 780,000,000.00元。扣除已支付的保荐及承销费（不含增值税）人民币7,000,000.00元后的募集 资金金额为773,000,000.00元，已由保荐机构中金公 ...

| 证券代码：603707 | 证券简称：健友股份 | 公告编号：2023-066 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 调整后的外汇套期保值业务额度及期限：公司及子公司使用自有资金及银行 授信额度开展保证金和权利金累计不超过 2 亿元人民币或其他等值外币的外 汇套期保值业务交易；公司及子公司进行外汇套期保值业务任一交易日持有 的最高合约价值累计不超过 30 亿元人民币或其他等值外币，有效期自董事 会审议通过之日起十二个月内。在上述额度及有效期内，资金可循环滚动使 用。 交易场所：在合规并满足公司套期保值业务条件的各大银行等金融机构进行 交易。 业务品种：公司进行外汇套期保值业务包括但不限于远期业务、掉期业务、 互换业务、期权业务、期货业务及其他外汇衍生产品业务。 履行的审议程序：公司于 2023 年 8 月 28 日召开第五届董事会第三次会议， 审议通过了《关于调整公司外汇套期保值业务额度的议案》。公司独立董事 发表了同意的独立意见，本议案无需提交公司股东大会审议。 特别风险提示：公司开展外汇套期保值业务遵循合法、谨慎、安全和有效的 原则，以 ...

南京健友生化制药股份有限公司 | 证券代码：603707 | 证券简称：健友股份 | 公告编号：2023-061 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 一、董事会会议召开情况 南京健友生化制药股份有限公司（以下简称"公司"）第五届董事会第三次 会议的通知已于 2023 年 8 月 21 日以电话及电子邮件的方式向各位董事发出，会 议于 2023 年 8 月 28 日上午 9 点整在公司会议室召开。会议应到董事 6 人，实到 董事 6 人，其中独立董事 2 人。 本次会议由董事长唐咏群先生主持。本次会议召集、召开符合《中华人民共 和国公司法》及有关法律、法规和《公司章程》的规定。 二、董事会会议审议情况 会议审议并通过了如下议案： 1、审议通过《关于公司 2023 半年度报告及其摘要的议案》 第五届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 公司董事会认为公司编制的 2023 年半年度报告及其摘要内容真实、准确、 完整，不存在虚 ...

| 证券代码：603707 | 证券简称：健友股份 | 公告编号：2023-065 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于增加使用自有资金进行现金管理额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、使用闲置自有资金进行现金管理额度调整的情况 公司于 2023 年 4 月 27 日召开第四届董事会第二十次会议，审议通过了《关 于使用闲置自有资金进行现金管理的议案》，同意公司使用额度不超过 200,000 万元（含）的自有资金进行现金管理。 由于公司经营情况良好，自有资金较为充沛，为了充分发挥公司资金的使用 调整后的现金管理额度及期限：南京健友生化制药股份有限公司（以下简称 "公司"）拟使用额度不超过 300,000 万元（含）的自有资金进行现金管理， 有效期自本次董事会审议通过之日起十二个月内。在上述额度及有效期内， 资金可循环滚动使用。 现金管理受托方：商业银行等金融机构 现金管理产品：本公 ...

南京健友生化制药股份有限公司 关于调整外汇套期保值业务额度的可行性分析报告 一、调整外汇套期保值业务的必要性 随着公司海外业务的不断拓展，外汇收支规模也不断增长，为有效规避外 汇市场的风险，防范汇率波动对公司经营业绩带来的不确定影响，更好地维护 公司及全体股东的利益，公司根据实际外汇收支规模与银行等金融机构开展外 汇套期保值业务，主动应对外汇汇率波动的风险，预计将有效控制风险敞口。 二、公司开展套期保值业务的可行性 公司进行外汇套期保值业务遵循合法合规、审慎、安全、有效的原则，不进 行以投机为目的的外汇交易，所有外汇套期保值业务均以正常业务经营为基础， 以规避和防范汇率风险为目的。但是进行外汇套期保值业务也会存在一定的风险： 1、汇率波动风险：在汇率走势与公司判断汇率波动方向发生大幅偏离的情 况下，公司锁定汇率后支出的成本可能超过不锁定时的成本支出，从而造成公司 损失； 2、履约风险：外汇套期保值业务存在合约到期无法履约造成违约而带来的 风险； 3、内部控制风险：外汇套期保值业务专业性较强，复杂程度较高，可能会 由于内部控制机制不完善而造成经营风险； 4、操作风险：由于外汇套期保值交易专业性较强，复杂程度较高 ...